Evidence map›Paper›PMID 21593262›Full record

ArticleJournal of clinical microbiology2011

Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?

Viral Vadwai, Catharina Boehme, Pamela Nabeta, Anjali Shetty, David Alland, Camilla Rodrigues

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 21 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 21 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. XpertThe Cochrane database of systematic reviews · 2018
    Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Isoniazid-resistant tuberculosis in children: a systematic review.The Pediatric infectious disease journal · 2013
    Pooled it

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Viral VadwaiPD Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai, India.
Catharina Boehme
Pamela Nabeta
Anjali Shetty
David Alland
Camilla Rodrigues

Funding

Sample Processing Cartridges for Rapid PCR TB DetectionR42AI052523 · NIAID · CEPHEID · PI ALLAND, DAVID · 2006 to 2008
$4.0M
Sample Processing Cartridges for Rapid PCR TB DetectionR41AI052523 · NIAID · CEPHEID · PI ALLAND, DAVID · 2002 to 2002
$376k
NIAID NIH HHS AI52523NIAID NIH HHS R41 AI052523NIAID NIH HHS R42 AI052523
6 · The paper itself

Abstract

Approximately 10 to 15% of tuberculosis (TB) cases in India are estimated to have extrapulmonary disease, and due to a lack of diagnostic means, they often remain untreated. The early detection of Mycobacterium tuberculosis and multidrug resistance is a priority in TB diagnosis to improve the successful treatment rate of TB and reduce transmission. The Xpert MTB/RIF (Xpert) test, recently endorsed by the World Health Organization for the detection of pulmonary TB, was evaluated to test its utility in 547 patients with suspected extrapulmonary tuberculosis. Five hundred forty-seven extrapulmonary specimens were split and processed simultaneously for both culture (solid and liquid) and Xpert testing. For culture, the sensitivity was low, 53% (150/283 specimens). Xpert sensitivity and specificity results were assessed in comparison to a composite reference standard made up of smear and culture results and clinical, radiological, and histological findings. The sensitivity of the Xpert assay was 81% (228/283 specimens) (64% [89/138] for smear-negative cases and 96% [139/145] for smear-positive cases), with a specificity of 99.6%. The sensitivity was found to be high for the majority of specimen types (63 to 100%) except for cerebrospinal fluid, the sensitivity of which was 29% (2/7 specimens). The Xpert test correctly identified 98% of phenotypic rifampin (RIF)-resistant cases and 94% of phenotypic RIF-susceptible cases. Sequencing of the 6 discrepant samples resolved 3 of them, resulting in an increased specificity of 98%. In conclusion, the results of this study suggest that the Xpert test also shows good potential for the diagnosis of extrapulmonary TB and that its ease of use makes it applicable for countries where TB is endemic.

Indexed as

Reagent Kits, DiagnosticAdolescentAdultAgedAged, 80 and overChildChild, PreschoolClinical Laboratory TechniquesFemaleHumansIndiaInfantLungMaleMiddle AgedMolecular Diagnostic TechniquesReagent Kits, Diagnostic

Identifiers

PMID21593262
PMCPMC3147857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.